Recurrent Breast Carcinoma Clinical Trial
Official title:
Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
Verified date | November 2019 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized phase III trial studies fulvestrant and lapatinib to see how well they work compared to fulvestrant and a placebo in treating postmenopausal women with stage III or stage IV breast cancer that is hormone receptor-positive. Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by lowering the amount of estrogen the body makes. Lapatinib may stop the growth of breast cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether fulvestrant is more effective with or without lapatinib in treating breast cancer.
Status | Completed |
Enrollment | 295 |
Est. completion date | July 2, 2014 |
Est. primary completion date | July 1, 2014 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologic, pathologic or cytologic diagnosis of cancer of the female breast in either primary or metastatic setting; histological documentation of metastatic/recurrent disease is not required if there is unequivocal clinical evidence for recurrence - Stage IV breast cancer (using American Joint Committee on Cancer [AJCC] criteria, 6th edition), or locally advanced (stage III) breast cancer not considered amenable to curative therapy - Patients with symptomatic brain metastases or other symptomatic central nervous system (CNS) metastases are not eligible for the study; no screening studies are required among asymptomatic patients; patients with previously treated brain metastases, who are free of symptoms referable to CNS disease and who are > 3 months from treatment for brain metastases are eligible - Tumors (as determined on pathology from either primary or metastatic sites) must be potentially sensitive to endocrine therapy, defined as expressing estrogen receptor (ER) and/or progesterone receptor (PgR) as determined immunohistochemical methods according to the local institution's standard protocol, >= 1% cells will be considered to be positive - The protocol has been amended to permit tumors with any HER2 status, though a determination of HER2 status must have been made; patients will be considered to be eligible if HER2 expression is documented by one of the following methods: - Immunohistochemistry (IHC) 0 (i.e., negative), 1+, 2+, or 3+ levels of expression, or - Gene amplification (fluorescent in situ hybridization [FISH]) positive or negative - Patients must have at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 2.0 cm with conventional techniques or as >= 1.0 cm with spiral computed tomography (CT) scan - Exception: Patients with lytic or blastic bone metastases as their only site of disease will be eligible for the study even though these patients are not considered to have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria; these patients will be evaluable for time to progression, but not response - Patients with all other lesions, including small lesions (longest diameter < 2.0 cm with conventional techniques or < 1.0 cm with spiral CT scan) and truly non-measurable lesions including those listed below are not eligible - Lesions that are considered non-measurable include the following: - Bone lesions (women with bone lesions will be eligible as described above) - Leptomeningeal disease - Ascites - Pleural/pericardial effusion - Inflammatory breast cancer - Lymphangitis cutis/pulmonitis - Abdominal masses that are not confirmed and followed by imaging techniques - Cystic lesions - Patients must have had one or two prior endocrine treatments for breast cancer in either the adjuvant or metastatic setting, exclusive of treatment-related amenorrhea or ovarian suppression; sequential use of two different third-generation aromatase inhibitors is considered "one" treatment; it is not required that tumors be resistant to such treatments; for example: - A patient with de novo metastatic breast cancer who had never received endocrine therapy is not eligible; - A patient who received adjuvant tamoxifen and subsequent therapy with an aromatase inhibitor (adjuvant or metastatic) is eligible; - A patient who received an aromatase inhibitor in either the adjuvant or metastatic setting, and who discontinued therapy after several months because of side effects, is eligible; - A patient who received an aromatase inhibitor in the adjuvant setting is eligible, regardless of whether they did or did not receive tamoxifen at some point; - A patient who received adjuvant tamoxifen, and subsequently a nonsteroidal aromatase inhibitor and a steroidal aromatase inhibitor for advanced breast cancer in the adjuvant or metastatic setting is eligible; - A patient who received adjuvant tamoxifen, and then a nonsteroidal aromatase inhibitor and subsequently megesterol acetate for advanced breast cancer is not eligible - Tumors potentially sensitive to endocrine therapy, defined as >= 3 months of prior endocrine therapy without disease progression in the adjuvant or metastatic setting - Patients must have had prior treatment in either the adjuvant or metastatic setting with a commercially available third-generation aromatase inhibitor (i.e. anastrozole, exemestane, or letrozole); it is not required that tumors be resistant to such therapies - Patients may have received up to one prior chemotherapy regimen for stage IV breast cancer; prior chemotherapy in the adjuvant and/or neoadjuvant setting is permitted; patients must have finished chemotherapy at least 1 week prior to starting protocol based treatment - Patients may have received prior trastuzumab therapy for stage IV breast cancer, in combination with up to one chemotherapy and/or endocrine therapy regimen, but that must have concluded at least 3 weeks prior to starting protocol-based therapy; prior trastuzumab therapy in the adjuvant and/or neoadjuvant setting is permitted, but must have concluded at least 3 weeks prior to starting protocol-based therapy - Prior therapy with commercially available inhibitor of EGFR (including but not limited to gefitinib, erlotinib, lapatinib or cetuximab) or experimental inhibitors of EGFR is prohibited - Patients may have initiated bisphosphonate therapy prior to study entry; such patients will have bone lesions considered evaluable for progression but not for response - Prior fulvestrant therapy is prohibited - Patients receiving a gonadotropin-releasing hormone (GnRH) agonist for ovarian suppression must remain on such therapy throughout the course of protocol treatment; patients must discontinue other endocrine treatments, including systemic hormone-replacement therapy and intravaginal estrogens prior to study entry; patients must have concluded radiation therapy prior to study entry; patients must be at least 1 week from prior chemotherapy or 3 weeks from prior trastuzumab therapy, with adequate recovery of bone marrow function and performance status - Patients must be postmenopausal women, defined as a woman fulfilling any of the following criteria: - Age >= 60 years; or - Age >= 45 years with an intact uterus and amenorrhea for 12 months or more; or - History of bilateral oophorectomy; or - Follicle stimulating hormone (FSH) levels within postmenopausal range according to the ranges established by the testing facility; or - Treatment with a GnRH agonist for ovarian suppression for at least 3 consecutive months prior to study registration, and remaining on such therapy throughout the course of protocol treatment - Women who are pregnant or nursing are not eligible for the study; clinicians should advise patients that there are no data for the safety of lapatinib or fulvestrant among pregnant patients, nor data on the impact of these agents on fertility or pregnancy - Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status 0-2 - Absence of pending visceral crisis, in the opinion of the treating physician - Absence of acquired or inherited bleeding disorder - Absence of need for therapeutic systemic anticoagulation (defined as maintaining international normalized ratio [INR] > 1.6); patients may take low-dose warfarin or aspirin (or equivalent) for maintenance of central venous catheter patency - Granulocytes >= 1,000/µl - Platelet count >= 100,000/µl - Creatinine =< 2 mg/dl - Total bilirubin =< 1.5 x upper limits of normal (ULN) unless due to Gilbert's syndrome - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN without liver metastases; =< 5 x ULN with liver metastases - INR =< 1.6 - Left ventricular ejection fraction (LVEF) within institutional limits of normal |
Country | Name | City | State |
---|---|---|---|
United States | Avera Cancer Institute-Aberdeen | Aberdeen | South Dakota |
United States | Abington Memorial Hospital | Abington | Pennsylvania |
United States | Cleveland Clinic Akron General | Akron | Ohio |
United States | Saint Anthony's Health | Alton | Illinois |
United States | American Fork Hospital / Huntsman Intermountain Cancer Center | American Fork | Utah |
United States | McFarland Clinic PC - Ames | Ames | Iowa |
United States | AnMed Health Hospital | Anderson | South Carolina |
United States | University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan |
United States | Hospital District Sixth of Harper County | Anthony | Kansas |
United States | Arroyo Grande Community | Arroyo Grande | California |
United States | PCR Oncology | Arroyo Grande | California |
United States | Mission Hospital | Asheville | North Carolina |
United States | Rush - Copley Medical Center | Aurora | Illinois |
United States | Greater Baltimore Medical Center | Baltimore | Maryland |
United States | Saint Agnes Hospital | Baltimore | Maryland |
United States | University of Maryland/Greenebaum Cancer Center | Baltimore | Maryland |
United States | Eastern Maine Medical Center | Bangor | Maine |
United States | Baton Rouge General Medical Center | Baton Rouge | Louisiana |
United States | Mary Bird Perkins Cancer Center | Baton Rouge | Louisiana |
United States | Bronson Battle Creek | Battle Creek | Michigan |
United States | Franciscan Saint Francis Health-Beech Grove | Beech Grove | Indiana |
United States | Mary Rutan Hospital | Bellefontaine | Ohio |
United States | PeaceHealth Saint Joseph Medical Center | Bellingham | Washington |
United States | Central Vermont Medical Center/National Life Cancer Treatment | Berlin | Vermont |
United States | Saint Luke's University Hospital-Bethlehem Campus | Bethlehem | Pennsylvania |
United States | University of Iowa Healthcare Cancer Services Quad Cities | Bettendorf | Iowa |
United States | Spectrum Health Big Rapids Hospital | Big Rapids | Michigan |
United States | Billings Clinic Cancer Center | Billings | Montana |
United States | Montana Cancer Consortium NCORP | Billings | Montana |
United States | Northern Rockies Radiation Oncology Center | Billings | Montana |
United States | Saint Vincent Frontier Cancer Center | Billings | Montana |
United States | Saint Vincent Healthcare | Billings | Montana |
United States | Mid Dakota Clinic | Bismarck | North Dakota |
United States | Saint Alexius Medical Center | Bismarck | North Dakota |
United States | Sanford Bismarck Medical Center | Bismarck | North Dakota |
United States | Saint Joseph Medical Center | Bloomington | Illinois |
United States | Boca Raton Regional Hospital | Boca Raton | Florida |
United States | Saint Luke's Mountain States Tumor Institute | Boise | Idaho |
United States | Beth Israel Deaconess Medical Center | Boston | Massachusetts |
United States | Brigham and Women's Hospital | Boston | Massachusetts |
United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
United States | Bozeman Deaconess Hospital | Bozeman | Montana |
United States | Harrison HealthPartners Hematology and Oncology-Bremerton | Bremerton | Washington |
United States | Saint Vincent's Medical Center | Bridgeport | Connecticut |
United States | Roswell Park Cancer Institute | Buffalo | New York |
United States | Providence Saint Joseph Medical Center/Disney Family Cancer Center | Burbank | California |
United States | University of Vermont and State Agricultural College | Burlington | Vermont |
United States | Fairview Ridges Hospital | Burnsville | Minnesota |
United States | Saint James Community Hospital and Cancer Treatment Center | Butte | Montana |
United States | Cooper Hospital University Medical Center | Camden | New Jersey |
United States | Aultman Health Foundation | Canton | Ohio |
United States | Graham Hospital Association | Canton | Illinois |
United States | Saint Francis Medical Center | Cape Girardeau | Missouri |
United States | Southeast Missouri Hospital | Cape Girardeau | Missouri |
United States | Memorial Hospital | Carthage | Illinois |
United States | East Bay Radiation Oncology Center | Castro Valley | California |
United States | Eden Hospital Medical Center | Castro Valley | California |
United States | Valley Medical Oncology Consultants-Castro Valley | Castro Valley | California |
United States | Sandra L Maxwell Cancer Center | Cedar City | Utah |
United States | Mercy Hospital | Cedar Rapids | Iowa |
United States | Oncology Associates at Mercy Medical Center | Cedar Rapids | Iowa |
United States | Cancer Center of Kansas - Chanute | Chanute | Kansas |
United States | UNC Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina |
United States | Saint Luke's Hospital | Chesterfield | Missouri |
United States | University of Chicago Comprehensive Cancer Center | Chicago | Illinois |
United States | University of Illinois | Chicago | Illinois |
United States | Adena Regional Medical Center | Chillicothe | Ohio |
United States | Case Western Reserve University | Cleveland | Ohio |
United States | Cleveland Clinic Foundation | Cleveland | Ohio |
United States | Medical Oncology and Hematology Associates-West Des Moines | Clive | Iowa |
United States | UCHealth Memorial Hospital Central | Colorado Springs | Colorado |
United States | Missouri Cancer Associates | Columbia | Missouri |
United States | University of Missouri - Ellis Fischel | Columbia | Missouri |
United States | Doctors Hospital | Columbus | Ohio |
United States | Grant Medical Center | Columbus | Ohio |
United States | Mount Carmel Health Center West | Columbus | Ohio |
United States | Riverside Methodist Hospital | Columbus | Ohio |
United States | New Hampshire Oncology Hematology PA-Concord | Concord | New Hampshire |
United States | Mercy Hospital | Coon Rapids | Minnesota |
United States | Heartland Oncology and Hematology LLP | Council Bluffs | Iowa |
United States | Danville Regional Medical Center | Danville | Virginia |
United States | Genesis Cancer Care Institute | Davenport | Iowa |
United States | Genesis Medical Center - East Campus | Davenport | Iowa |
United States | Dayton Veterans Affairs Medical Center | Dayton | Ohio |
United States | Good Samaritan Hospital - Dayton | Dayton | Ohio |
United States | Grandview Hospital | Dayton | Ohio |
United States | Miami Valley Hospital | Dayton | Ohio |
United States | Miami Valley Hospital North | Dayton | Ohio |
United States | Decatur Memorial Hospital | Decatur | Illinois |
United States | Heartland Cancer Research NCORP | Decatur | Illinois |
United States | Grady Memorial Hospital | Delaware | Ohio |
United States | Iowa Lutheran Hospital | Des Moines | Iowa |
United States | Iowa Methodist Medical Center | Des Moines | Iowa |
United States | Iowa-Wide Oncology Research Coalition NCORP | Des Moines | Iowa |
United States | Medical Oncology and Hematology Associates-Des Moines | Des Moines | Iowa |
United States | Medical Oncology and Hematology Associates-Laurel | Des Moines | Iowa |
United States | Mercy Capitol | Des Moines | Iowa |
United States | Mercy Medical Center - Des Moines | Des Moines | Iowa |
United States | Cancer Center of Kansas - Dodge City | Dodge City | Kansas |
United States | Essentia Health Cancer Center | Duluth | Minnesota |
United States | Essentia Health Saint Mary's Medical Center | Duluth | Minnesota |
United States | Miller-Dwan Hospital | Duluth | Minnesota |
United States | Saint Luke's Hospital of Duluth | Duluth | Minnesota |
United States | Duke University Medical Center | Durham | North Carolina |
United States | Hematology Oncology Associates of Central New York-East Syracuse | East Syracuse | New York |
United States | University of Maryland Shore Medical Center at Easton | Easton | Maryland |
United States | Fairview-Southdale Hospital | Edina | Minnesota |
United States | Cancer Center of Kansas - El Dorado | El Dorado | Kansas |
United States | Elkhart Clinic | Elkhart | Indiana |
United States | Elkhart General Hospital | Elkhart | Indiana |
United States | Union Hospital of Cecil County | Elkton | Maryland |
United States | Bay Area Breast Surgeons Inc | Emeryville | California |
United States | Green Bay Oncology - Escanaba | Escanaba | Michigan |
United States | Eureka Hospital | Eureka | Illinois |
United States | Saint Anne's Hospital | Fall River | Massachusetts |
United States | Blanchard Valley Hospital | Findlay | Ohio |
United States | Poudre Valley Hospital | Fort Collins | Colorado |
United States | Cancer Center of Kansas - Fort Scott | Fort Scott | Kansas |
United States | Fort Wayne Medical Oncology and Hematology Inc-Parkview | Fort Wayne | Indiana |
United States | Atrium Medical Center-Middletown Regional Hospital | Franklin | Ohio |
United States | Frederick Memorial Hospital | Frederick | Maryland |
United States | Valley Medical Oncology Consultants-Fremont | Fremont | California |
United States | Unity Hospital | Fridley | Minnesota |
United States | Galesburg Cottage Hospital | Galesburg | Illinois |
United States | Illinois CancerCare-Galesburg | Galesburg | Illinois |
United States | Western Illinois Cancer Treatment Center | Galesburg | Illinois |
United States | CaroMont Regional Medical Center | Gastonia | North Carolina |
United States | Glendale Memorial Hospital and Health Center | Glendale | California |
United States | Addison Gilbert Hospital | Gloucester | Massachusetts |
United States | Southeastern Medical Oncology Center-Goldsboro | Goldsboro | North Carolina |
United States | Wayne Memorial Hospital | Goldsboro | North Carolina |
United States | Goshen Center for Cancer Care | Goshen | Indiana |
United States | Altru Cancer Center | Grand Forks | North Dakota |
United States | Cancer Research Consortium of West Michigan NCORP | Grand Rapids | Michigan |
United States | Mercy Health Saint Mary's | Grand Rapids | Michigan |
United States | Spectrum Health at Butterworth Campus | Grand Rapids | Michigan |
United States | Benefis Healthcare- Sletten Cancer Institute | Great Falls | Montana |
United States | Berdeaux, Donald MD (UIA Investigator) | Great Falls | Montana |
United States | Great Falls Clinic | Great Falls | Montana |
United States | Green Bay Oncology at Saint Vincent Hospital | Green Bay | Wisconsin |
United States | Green Bay Oncology Limited at Saint Mary's Hospital | Green Bay | Wisconsin |
United States | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay | Wisconsin |
United States | Saint Vincent Hospital Cancer Center Green Bay | Green Bay | Wisconsin |
United States | Prisma Health Cancer Institute - Eastside | Greenville | South Carolina |
United States | Saint Francis Hospital | Greenville | South Carolina |
United States | Mason District Hospital | Havana | Illinois |
United States | Saint Rose Hospital | Hayward | California |
United States | Saint Peter's Community Hospital | Helena | Montana |
United States | Maria Parham Hospital | Henderson | North Carolina |
United States | Margaret R Pardee Memorial Hospital | Hendersonville | North Carolina |
United States | Holland Community Hospital | Holland | Michigan |
United States | New Hampshire Oncology Hematology PA-Hooksett | Hooksett | New Hampshire |
United States | Hopedale Medical Complex - Hospital | Hopedale | Illinois |
United States | Hutchinson Area Health Care | Hutchinson | Minnesota |
United States | Cancer Center of Kansas-Independence | Independence | Kansas |
United States | Cleveland Clinic Cancer Center Independence | Independence | Ohio |
United States | Community Cancer Center East | Indianapolis | Indiana |
United States | Community Cancer Center North | Indianapolis | Indiana |
United States | University of Iowa/Holden Comprehensive Cancer Center | Iowa City | Iowa |
United States | Green Bay Oncology - Iron Mountain | Iron Mountain | Michigan |
United States | University of Mississippi Medical Center | Jackson | Mississippi |
United States | Mercyhealth Hospital and Cancer Center - Janesville | Janesville | Wisconsin |
United States | Joliet Oncology-Hematology Associates Limited | Joliet | Illinois |
United States | Freeman Health System | Joplin | Missouri |
United States | Borgess Medical Center | Kalamazoo | Michigan |
United States | Bronson Methodist Hospital | Kalamazoo | Michigan |
United States | West Michigan Cancer Center | Kalamazoo | Michigan |
United States | Glacier Oncology PLLC | Kalispell | Montana |
United States | Kalispell Medical Oncology | Kalispell | Montana |
United States | Kalispell Regional Medical Center | Kalispell | Montana |
United States | Presence Saint Mary's Hospital | Kankakee | Illinois |
United States | University of Kansas Cancer Center | Kansas City | Kansas |
United States | Keesler Medical Center | Keesler Air Force Base | Mississippi |
United States | Kadlec Clinic Hematology and Oncology | Kennewick | Washington |
United States | Kettering Medical Center | Kettering | Ohio |
United States | Kewanee Hospital | Kewanee | Illinois |
United States | Cancer Center of Kansas-Kingman | Kingman | Kansas |
United States | Wellmont Holston Valley Hospital and Medical Center | Kingsport | Tennessee |
United States | Vidant Oncology-Kinston | Kinston | North Carolina |
United States | University of Tennessee - Knoxville | Knoxville | Tennessee |
United States | Community Howard Regional Health | Kokomo | Indiana |
United States | Gundersen Lutheran Medical Center | La Crosse | Wisconsin |
United States | AMITA Health Adventist Medical Center | La Grange | Illinois |
United States | IU Health La Porte Hospital | La Porte | Indiana |
United States | LRGHealthcare-Lakes Region General Hospital | Laconia | New Hampshire |
United States | Fairfield Medical Center | Lancaster | Ohio |
United States | Saint Mary Medical and Regional Cancer Center | Langhorne | Pennsylvania |
United States | University Medical Center of Southern Nevada | Las Vegas | Nevada |
United States | Lawrence Memorial Hospital | Lawrence | Kansas |
United States | Beebe Medical Center | Lewes | Delaware |
United States | Cancer Center of Kansas-Liberal | Liberal | Kansas |
United States | Southwest Medical Center | Liberal | Kansas |
United States | Saint Rita's Medical Center | Lima | Ohio |
United States | Meeker County Memorial Hospital | Litchfield | Minnesota |
United States | University of Arkansas for Medical Sciences | Little Rock | Arkansas |
United States | Saint Barnabas Medical Center | Livingston | New Jersey |
United States | Logan Regional Hospital | Logan | Utah |
United States | Doctors Carrol, Sheth, Raghavan | Louisville | Kentucky |
United States | Lowell General Hospital | Lowell | Massachusetts |
United States | Southeastern Regional Medical Center | Lumberton | North Carolina |
United States | Mcdonough District Hospital | Macomb | Illinois |
United States | Dean Hematology and Oncology Clinic | Madison | Wisconsin |
United States | Elliot Hospital | Manchester | New Hampshire |
United States | Holy Family Memorial Hospital | Manitowoc | Wisconsin |
United States | Minnesota Oncology Hematology PA-Maplewood | Maplewood | Minnesota |
United States | Saint John's Hospital - Healtheast | Maplewood | Minnesota |
United States | Marietta Memorial Hospital | Marietta | Ohio |
United States | Bay Area Medical Center | Marinette | Wisconsin |
United States | Fremont - Rideout Cancer Center | Marysville | California |
United States | Mercy Medical Center - North Iowa | Mason City | Iowa |
United States | Loyola University Medical Center | Maywood | Illinois |
United States | University of Tennessee Health Science Center | Memphis | Tennessee |
United States | Franciscan Saint Anthony Health-Michigan City | Michigan City | Indiana |
United States | Mid-Michigan Medical Center - Midland | Midland | Michigan |
United States | Abbott-Northwestern Hospital | Minneapolis | Minnesota |
United States | Hennepin County Medical Center | Minneapolis | Minnesota |
United States | Virginia Piper Cancer Institute | Minneapolis | Minnesota |
United States | Trinity Cancer Care Center | Minot | North Dakota |
United States | Saint Joseph Regional Medical Center-Mishawaka | Mishawaka | Indiana |
United States | Community Medical Hospital | Missoula | Montana |
United States | Guardian Oncology and Center for Wellness | Missoula | Montana |
United States | Montana Cancer Specialists | Missoula | Montana |
United States | Saint Patrick Hospital - Community Hospital | Missoula | Montana |
United States | Morristown Medical Center | Morristown | New Jersey |
United States | Virtua Memorial | Mount Holly | New Jersey |
United States | Northern Westchester Hospital | Mount Kisco | New York |
United States | Good Samaritan Regional Health Center | Mount Vernon | Illinois |
United States | Skagit Valley Hospital | Mount Vernon | Washington |
United States | El Camino Hospital | Mountain View | California |
United States | Palo Alto Medical Foundation-Camino Division | Mountain View | California |
United States | Cottonwood Hospital Medical Center | Murray | Utah |
United States | Intermountain Medical Center | Murray | Utah |
United States | Mercy Health Mercy Campus | Muskegon | Michigan |
United States | Mercy Health Partners-Hackley Campus | Muskegon | Michigan |
United States | Yale University | New Haven | Connecticut |
United States | Louisiana State University Health Science Center | New Orleans | Louisiana |
United States | University Medical Center New Orleans | New Orleans | Louisiana |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Christiana Care Health System-Christiana Hospital | Newark | Delaware |
United States | Licking Memorial Hospital | Newark | Ohio |
United States | Cancer Center of Kansas - Newton | Newton | Kansas |
United States | Bromenn Regional Medical Center | Normal | Illinois |
United States | Community Cancer Center Foundation | Normal | Illinois |
United States | Southwest VA Regional Cancer Center | Norton | Virginia |
United States | Alta Bates Summit Medical Center - Summit Campus | Oakland | California |
United States | Bay Area Tumor Institute | Oakland | California |
United States | Hematology and Oncology Associates-Oakland | Oakland | California |
United States | Highland General Hospital | Oakland | California |
United States | Tom K Lee Inc | Oakland | California |
United States | Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls | Wisconsin |
United States | McKay-Dee Hospital Center | Ogden | Utah |
United States | Nebraska Methodist Hospital | Omaha | Nebraska |
United States | Illinois CancerCare-Ottawa Clinic | Ottawa | Illinois |
United States | Ottawa Regional Hospital and Healthcare Center | Ottawa | Illinois |
United States | Ottumwa Regional Health Center | Ottumwa | Iowa |
United States | Granville Medical Center | Oxford | North Carolina |
United States | Cancer Center of Kansas - Parsons | Parsons | Kansas |
United States | OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center | Pekin | Illinois |
United States | Pekin Hospital | Pekin | Illinois |
United States | Illinois CancerCare-Peoria | Peoria | Illinois |
United States | Methodist Medical Center of Illinois | Peoria | Illinois |
United States | OSF Saint Francis Medical Center | Peoria | Illinois |
United States | Proctor Hospital | Peoria | Illinois |
United States | Illinois Valley Hospital | Peru | Illinois |
United States | Valley Radiation Oncology | Peru | Illinois |
United States | FirstHealth of the Carolinas-Moore Regional Hospital | Pinehurst | North Carolina |
United States | Via Christi Hospital-Pittsburg | Pittsburg | Kansas |
United States | Valley Care Health System - Pleasanton | Pleasanton | California |
United States | Valley Medical Oncology Consultants | Pleasanton | California |
United States | Portneuf Medical Center | Pocatello | Idaho |
United States | Cancer Center of Kansas - Pratt | Pratt | Kansas |
United States | Perry Memorial Hospital | Princeton | Illinois |
United States | Utah Valley Regional Medical Center | Provo | Utah |
United States | Duke Raleigh Hospital | Raleigh | North Carolina |
United States | Rapid City Regional Hospital | Rapid City | South Dakota |
United States | Reid Health | Richmond | Indiana |
United States | Virginia Commonwealth University/Massey Cancer Center | Richmond | Virginia |
United States | West Suburban Medical Center | River Forest | Illinois |
United States | North Memorial Medical Health Center | Robbinsdale | Minnesota |
United States | OSF Saint Anthony Medical Center | Rockford | Illinois |
United States | Person Memorial Hospital | Roxboro | North Carolina |
United States | William Beaumont Hospital-Royal Oak | Royal Oak | Michigan |
United States | Rutherford Hospital | Rutherfordton | North Carolina |
United States | University of California Davis Comprehensive Cancer Center | Sacramento | California |
United States | Dixie Medical Center Regional Cancer Center | Saint George | Utah |
United States | Lakeland Medical Center Saint Joseph | Saint Joseph | Michigan |
United States | Marie Yeager Cancer Center | Saint Joseph | Michigan |
United States | Oncology Care Associates PLLC | Saint Joseph | Michigan |
United States | Center for Cancer Care and Research | Saint Louis | Missouri |
United States | Mercy Hospital Saint Louis | Saint Louis | Missouri |
United States | Missouri Baptist Medical Center | Saint Louis | Missouri |
United States | Saint Louis-Cape Girardeau CCOP | Saint Louis | Missouri |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | Metro Minnesota Community Oncology Research Consortium | Saint Louis Park | Minnesota |
United States | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park | Minnesota |
United States | Regions Hospital | Saint Paul | Minnesota |
United States | Saint Joseph's Hospital - Healtheast | Saint Paul | Minnesota |
United States | United Hospital | Saint Paul | Minnesota |
United States | Cancer Center of Kansas - Salina | Salina | Kansas |
United States | Salinas Valley Memorial | Salinas | California |
United States | Huntsman Cancer Institute/University of Utah | Salt Lake City | Utah |
United States | Intermountain Health Care | Salt Lake City | Utah |
United States | LDS Hospital | Salt Lake City | Utah |
United States | Utah Cancer Specialists-Salt Lake City | Salt Lake City | Utah |
United States | Kaiser Permanente-San Diego Mission | San Diego | California |
United States | UCSF Medical Center-Mount Zion | San Francisco | California |
United States | Zuckerberg San Francisco General Hospital | San Francisco | California |
United States | Doctors Medical Center- JC Robinson Regional Cancer Center | San Pablo | California |
United States | Kaiser Permanente Washington | Seattle | Washington |
United States | Minor and James Medical PLLC | Seattle | Washington |
United States | Swedish Medical Center-First Hill | Seattle | Washington |
United States | University of Washington Medical Center | Seattle | Washington |
United States | Saint Francis Regional Medical Center | Shakopee | Minnesota |
United States | Welch Cancer Center | Sheridan | Wyoming |
United States | Mercy Medical Center-Sioux City | Sioux City | Iowa |
United States | Saint Luke's Regional Medical Center | Sioux City | Iowa |
United States | Siouxland Regional Cancer Center | Sioux City | Iowa |
United States | Avera McKennan Hospital and University Health Center | Sioux Falls | South Dakota |
United States | Medical X-Ray Center | Sioux Falls | South Dakota |
United States | Sanford Cancer Center Oncology Clinic | Sioux Falls | South Dakota |
United States | Sanford USD Medical Center - Sioux Falls | Sioux Falls | South Dakota |
United States | Memorial Hospital of South Bend | South Bend | Indiana |
United States | Michiana Hematology Oncology PC-South Bend | South Bend | Indiana |
United States | Northern Indiana Cancer Research Consortium | South Bend | Indiana |
United States | Spartanburg Medical Center | Spartanburg | South Carolina |
United States | Cancer Care Northwest - Spokane South | Spokane | Washington |
United States | Evergreen Hematology and Oncology PS | Spokane | Washington |
United States | Saint Margaret's Hospital | Spring Valley | Illinois |
United States | Memorial Medical Center | Springfield | Illinois |
United States | Springfield Regional Medical Center | Springfield | Ohio |
United States | Staten Island University Hospital | Staten Island | New York |
United States | Green Bay Oncology - Sturgeon Bay | Sturgeon Bay | Wisconsin |
United States | Overlook Hospital | Summit | New Jersey |
United States | State University of New York Upstate Medical University | Syracuse | New York |
United States | Cotton O'Neil Cancer Center / Stormont Vail Health | Topeka | Kansas |
United States | Smilow Cancer Hospital-Torrington Care Center | Torrington | Connecticut |
United States | Munson Medical Center | Traverse City | Michigan |
United States | Saint Francis Medical Center | Trenton | New Jersey |
United States | Upper Valley Medical Center | Troy | Ohio |
United States | Gene Upshaw Memorial Tahoe Forest Cancer Center | Truckee | California |
United States | Carle Cancer Center | Urbana | Illinois |
United States | Northbay Cancer Center | Vacaville | California |
United States | Inspira Medical Center Vineland | Vineland | New Jersey |
United States | Virtua Voorhees | Voorhees | New Jersey |
United States | Ridgeview Medical Center | Waconia | Minnesota |
United States | MedStar Georgetown University Hospital | Washington | District of Columbia |
United States | Sibley Memorial Hospital | Washington | District of Columbia |
United States | Harold Leever Regional Cancer Center | Waterbury | Connecticut |
United States | Cancer Center of Kansas - Wellington | Wellington | Kansas |
United States | Wenatchee Valley Hospital and Clinics | Wenatchee | Washington |
United States | Saint Ann's Hospital | Westerville | Ohio |
United States | Ascension Via Christi Hospitals Wichita | Wichita | Kansas |
United States | Associates In Womens Health | Wichita | Kansas |
United States | Cancer Center of Kansas - Wichita | Wichita | Kansas |
United States | Cancer Center of Kansas-Wichita Medical Arts Tower | Wichita | Kansas |
United States | Rice Memorial Hospital | Willmar | Minnesota |
United States | Clinton Memorial Hospital | Wilmington | Ohio |
United States | Cancer Center of Kansas - Winfield | Winfield | Kansas |
United States | Wake Forest University Health Sciences | Winston-Salem | North Carolina |
United States | Minnesota Oncology Hematology PA-Woodbury | Woodbury | Minnesota |
United States | Woodwinds Health Campus | Woodbury | Minnesota |
United States | Cleveland Clinic Wooster Family Health and Surgery Center | Wooster | Ohio |
United States | UMass Memorial Medical Center - University Campus | Worcester | Massachusetts |
United States | Wright-Patterson Medical Center | Wright-Patterson Air Force Base | Ohio |
United States | Metro Health Hospital | Wyoming | Michigan |
United States | Greene Memorial Hospital | Xenia | Ohio |
United States | York Hospital | York | Maine |
United States | Genesis Healthcare System Cancer Care Center | Zanesville | Ohio |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Progression-free Survival for Participants With HER2-negative Tumors | PFS was defined as the interval from study entry until disease progression or death resulting from any cause, which ever occurred first. | Up to 5 years | |
Other | Progression-free Survival for Participants With HER2-positive Tumors | PFS was defined as the interval from study entry until disease progression or death resulting from any cause, whichever occurred first. | Up to 5 years | |
Other | Objective Tumor Response Rate for Participants With HER2-negative Tumors | Response was defined by the RECIST. A responding participant had either a Complete Response (disappearance of all target lesions) or Partial Response (30% decrease in sum of longest diameter of target lesions). The response rate of measurable tumors will be estimated with its 95% confidence interval according to treatment arm. | Up to 5 years | |
Other | Objective Tumor Response Rate for Participants With HER2-positive Tumors | Response was defined by the RECIST. A responding participant had either a Complete Response (disappearance of all target lesions) or Partial Response (30% decrease in sum of longest diameter of target lesions). The response rate of measurable tumors will be estimated with its 95% confidence interval according to treatment arm. | Up to 5 years | |
Primary | Progression-free Survival (PFS) | PFS was defined as the interval from study entry until disease progression or death resulting from any cause, which ever occurred first. Progression is defined as a 20% increase in the sum of longest diameter of target lesions (per RECIST criteria). | Interval from randomization until disease progression or death, whichever occurs first, assessed up to 5 years | |
Secondary | Objective Tumor Response Rate | Response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST). A responding participant had either a Complete Response (disappearance of all target lesions) or Partial Response (30% decrease in sum of longest diameter of target lesions). The response rate of measurable tumors will be estimated with its 95% confidence interval according to treatment arm. | Up to 5 years | |
Secondary | Overall Survival (OS) | Overall survival was measured as the interval from study entry until death, from any cause, or last contact. | Study entry to death or last follow-up, up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04052555 -
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04521764 -
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
|
Phase 1 | |
Completed |
NCT00100750 -
Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Suspended |
NCT03737695 -
Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer
|
||
Active, not recruiting |
NCT02595905 -
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
|
Phase 2 | |
Terminated |
NCT02149173 -
F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy
|
N/A | |
Recruiting |
NCT03213041 -
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT04529044 -
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
|
Phase 2 | |
Completed |
NCT00699491 -
Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03364348 -
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
|
Phase 1 | |
Terminated |
NCT01149356 -
RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer
|
Phase 1 | |
Completed |
NCT01964924 -
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
|
Phase 2 | |
Completed |
NCT00785291 -
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
|
Phase 3 | |
Terminated |
NCT02370264 -
Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer
|
N/A | |
Terminated |
NCT01071564 -
RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery
|
Phase 1 | |
Terminated |
NCT00998738 -
Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
|
Phase 3 | |
Active, not recruiting |
NCT00520975 -
First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
|
Phase 3 | |
Completed |
NCT01251874 -
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03281902 -
Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy
|
||
Recruiting |
NCT03987555 -
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
|